Isocyperol

Isocyperol

SCHEMBL29477342

C=C(C)[C@@H]1CC[C@@]2(C)CC[C@@H](O)C(=C)C2C1

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.44
TP53 P04637 1/20 0.34
TSHR P16473 1/20 0.34
TRPA1 O75762 1/20 0.34
ACHE P22303 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA4 P22748 1/20 0.33
CA7 P43166 1/20 0.33
CA9 Q16790 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.31
POLB P06746 1/20 0.31
NLRP3 Q96P20 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Isocyperol SCHEMBL16663911 1.00 PTPN1 (0.44) PTPN1TP53TSHRTRPA1ACHE
Beta-Selinene SCHEMBL309336 0.78 PTPN1 (0.64) PTPN1TRPA1CA1CA2CA4
Beta-Selinene SCHEMBL28349419 0.78 PTPN1 (0.64) PTPN1TRPA1CA1CA2CA4
Beta-Selinene SCHEMBL17629434 0.78 PTPN1 (0.64) PTPN1TRPA1CA1CA2CA4
Beta-Selinene SCHEMBL30105712 0.78 PTPN1 (0.64) PTPN1TRPA1CA1CA2CA4
Beta-Selinene SCHEMBL29975200 0.78 PTPN1 (0.64) PTPN1TRPA1CA1CA2CA4
SCHEMBL3438652 0.73 HDAC6 (0.47) PTPN1TP53TSHRCA1CA2
SCHEMBL17627664 0.73 HDAC6 (0.47) PTPN1TP53TSHRCA1CA2
SCHEMBL567659 0.73 HDAC6 (0.47) PTPN1TP53TSHRCA1CA2
SCHEMBL30105630 0.73 HDAC6 (0.47) PTPN1TP53TSHRCA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4229639-A1 METHOD AND SYSTEMS FOR PHYTOMEDICINE ANALYTICS FOR RESEARCH OPTIMIZATION AT SCALE GBS Global Biopharma, Inc. (CA) 2023-08-23 EP claimed
WO-2022081889-A1 METHOD AND SYSTEMS FOR PHYTOMEDICINE ANALYTICS FOR RESEARCH OPTIMIZATION AT SCALE GBS GLOBAL BIOPHARMA, INC. (CA) 2022-04-21 WO claimed
US-20260034186-A1 ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS RIZUN NODARI (US) 2026-02-05 US disclosed
US-20260027136-A1 CANNABIS BASED THERAPEUTIC AND METHOD OF USE YUZU LV LLC (US) 2026-01-29 US disclosed
US-12458653-B2 Cannabis based therapeutic and method of use YUZU LV LLC (US) 2025-11-04 US disclosed
US-12427176-B2 Enriched mineral pitch resin products and methods of manufacturing enriched mineral pitch resin products RIZUN NODARI (US) 2025-09-30 US disclosed
US-12303488-B2 Cannabis based therapeutic and method of use YUZU LV LLC (US) 2025-05-20 US disclosed
US-20250137015-A1 YEAST PLATFORM FOR RENEWABLE INDUSTRIAL TERPENE PRODUCTION Wang, Zhen (US) 2025-05-01 US disclosed
EP-4417252-A2 CANNABIS BASED THERAPEUTIC AND METHOD OF USE Yuzu LV LLC (US) 2024-08-21 EP disclosed
US-20240216456-A1 ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS RIZUN NODARI (US) 2024-07-04 US disclosed
US-20240216457-A1 ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS RIZUN NODARI (US) 2024-07-04 US disclosed
US-20230346739-A1 CANNABIS BASED THERAPEUTIC AND METHOD OF USE YUZU LV LLC 2023-11-02 US disclosed
US-20230293480-A1 CANNABIS BASED THERAPEUTIC AND METHOD OF USE YUZU LV LLC 2023-09-21 US disclosed
US-20230293555-A1 COMPOSITIONS COMPRISING CANNABIDIOL AND FLAVANONES YUZU LV LLC 2023-09-21 US disclosed
US-11684604-B2 Cannabis based therapeutic and method of use YUZU LV LLC (US) 2023-06-27 US disclosed
CN-115581742-A A Chinese medicinal composition for treating mammary gland diseases, and its preparation method 东莞市云道医疗投资有限公司 2023-01-10 CN disclosed
US-20220387537-A1 ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS RIZUN NODARI (US) 2022-12-08 US disclosed
US-20220291237-A1 Gene Expression Inflammatory Age and Its Uses Edifice Health, Inc. (US) 2022-09-15 US disclosed
US-20220130493-A1 METHOD AND SYSTEMS FOR PHYTOMEDICINE ANALYTICS FOR RESEARCH OPTIMIZATION AT SCALE GBS GLOBAL BIOPHARMA, INC. (CA) 2022-04-28 US disclosed
WO-2022081889-A1 METHOD AND SYSTEMS FOR PHYTOMEDICINE ANALYTICS FOR RESEARCH OPTIMIZATION AT SCALE GBS GLOBAL BIOPHARMA, INC. (CA) 2022-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11684604-B2 Cannabis based therapeutic and method of use CNR2, CNR1, OPRK1 PTPN1 2536/4885TP53 4852/4885TSHR 4247/4885
US-20260027136-A1 CANNABIS BASED THERAPEUTIC AND METHOD OF USE CNR1, CNR2, OPRM1 PTPN1 1893/4885TP53 4521/4885TSHR 4394/4885
US-20260034186-A1 ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS TRPV1, SOST, RUNX1 PTPN1 4282/4885TP53 3395/4885TSHR 3626/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.